Maryland Code, Health-General § 19-308.11

(1) Means a drug approved by the U.S. Food and Drug Administration for the treatment of opioid use disorder; and

(2) Does not include a drug administered to mitigate opioid-related overdose symptoms.

(1) Provide to a patient before discharging the patient appropriate, evidence-based interventions that reduce the risk of subsequent harm and fatality following an opioid-related overdose or a visit for an opioid-related emergency medical condition;

(2) Possess at least one formulation of each U.S. Food and Drug Administration-approved full opioid agonist and partial opioid agonist used for the treatment of opioid use disorder; and

(3) Treat a patient who presents in a hospital emergency department for care and treatment of an opioid-related overdose or opioid-related emergency medical condition with a medication for opioid use disorder if the treatment:

(1) Any requirement by the Department regarding prescribing opioid agonist treatment;

(2) Uniform practices for screening and diagnosing individuals who present with an opioid-related overdose or opioid-related emergency medical condition for an opioid use disorder based on the criteria in the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders;

(3) Uniform practices for offering and administering opioid agonist medication to treat an opioid-related overdose or opioid use disorder; and

(4) Uniform practices to identify community-based treatment services that are appropriate for:

(1) Make a referral of the patient to an appropriate provider or facility for a timely appointment, when possible, to voluntarily continue treatment in the community; and

(2) Work with peer support professionals, as available, or other resources to assist the patient in accessing the identified treatment services.